The visual read of the tau PET led to a change in the diagnosis of 7.5% of the total population with 11.5% of those with a pre-PET AD diagnosis changing to a post-PET non-AD diagnosis and 4.0% of those with a pre-PET non-AD diagnosis changing to a post-PET AD diagnosis. This evidence concerns the gene MAPT and Alzheimer disease.